Presentation is loading. Please wait.

Presentation is loading. Please wait.

The Autophagy Inhibitor Chloroquine Overcomes the Innate Resistance of Wild-Type EGFR Non-Small-Cell Lung Cancer Cells to Erlotinib  Yiyu Zou, PhD, Yi-He.

Published byAngela Hutchinson Modified over 5 years ago

Similar presentations

Presentation on theme: "The Autophagy Inhibitor Chloroquine Overcomes the Innate Resistance of Wild-Type EGFR Non-Small-Cell Lung Cancer Cells to Erlotinib  Yiyu Zou, PhD, Yi-He."— Presentation transcript:

1 The Autophagy Inhibitor Chloroquine Overcomes the Innate Resistance of Wild-Type EGFR Non-Small-Cell Lung Cancer Cells to Erlotinib  Yiyu Zou, PhD, Yi-He Ling, PhD, Juan Sironi, PhD, Edward L. Schwartz, PhD, Roman Perez-Soler, MD, Bilal Piperdi, MD  Journal of Thoracic Oncology  Volume 8, Issue 6, Pages (June 2013) DOI: /JTO.0b013e31828c7210 Copyright © 2013 International Association for the Study of Lung Cancer Terms and Conditions

2 FIGURE 1 Erlotinib induces autophagy in human NSCLC cell lines. A, Cells were treated with 2 μM of erlotinib or with the same volume of medium containing 0.1% DMSO as a control for 72 hours. After treatment, cells were incubated with 50 μM of MDC for 15 minutes, and MDC-positive staining cells were analyzed with fluorescence microscopy. Autophagy percentage was assessed by counting MDC-positive cells out of 200 cells from each group; values are means ± SD of three experiments. *p value was less than 0.05 compared with control. B, Electron microscopy showed the ultrastructure of H322 and H460 cells after treatment with 2 μM of erlotinib for 72 hours. Arrows show autophagic vacuoles, including residual digested material and empty vacuoles. C, To assess the effect of knockdown of Atg-5 expression on erlotinib-induced cell death, cells were transiently transfected for 24 hours with Atg-5 siRNA, or with mock or no siRNA. After transfection, cells were treated with 4 μM of erlotinib for an additional 24 hours. After treatment, the levels of Atg-5, LC3-I, and LC3-II were assessed by immunoblot analysis. D, Cells were transfected with Atg-5 or mock-siRNA and treated with 4 μM of erlotinib as in (C). After incubation for 10 days, the colonies were counted and were expressed relative to control. Data are means ± SD of three independent experiments, *p < 0.05, **p < MDC, monodansylcaverine; N, nucleus; NSCLC, non–small-cell lung cancer. Journal of Thoracic Oncology 2013 8, DOI: ( /JTO.0b013e31828c7210) Copyright © 2013 International Association for the Study of Lung Cancer Terms and Conditions

3 FIGURE 2 Synergistic interactions of erlotinib and chloroquine in human NSCLC cell lines. A and B, NSCLC cells (103/well) were plated in 6-well plates overnight, and then treated with erlotinib (2 μM) and CQ (5 and 10 μM) alone, or in combination. After 10 days, plates were stained (A) and the number of colonies was quantified (B). Data are means ± SD of three independent experiments. *p < 0.05, and **p < 0.01 compared with erlotinib alone. C and D, Cells (103/well) were plated in 96-well plates overnight, and then treated with various concentrations of erlotinib or CQ alone, or with the combination of both agents with 1:5 molar ratio. After 7 days cell numbers were determined by an MTT assay (C), and the CI (D) was determined using CalcuSyn software. Data points with a CI < 1, indicate a synergistic interaction between the drugs. CQ, chloroquine; NSCLC, non–small-cell lung cancer; CI, combination index. Journal of Thoracic Oncology 2013 8, DOI: ( /JTO.0b013e31828c7210) Copyright © 2013 International Association for the Study of Lung Cancer Terms and Conditions

4 FIGURE 3 Cotreatment with CQ did not further impact erlotinib-induced suppression of EGFR, AKT, and ERK1/2 phosphorylation in NSCLC cell lines. Cells were treated with 2 μM of erlotinib, 10 μM of CQ alone, or with a combination of both agents for 24 hours, and then were treated with EGF for 10 minutes (30 ng/ml). After treatment, cells were harvested and cell extracts were made for assay of total and phosphorylated EGFR, AKT, and ERK by immunoblot. β-Actin was used as sample loading control. NSCLC, non–small-cell lung cancer; EGFR, epidermal growth factor receptor; CQ, chloroquine. Journal of Thoracic Oncology 2013 8, DOI: ( /JTO.0b013e31828c7210) Copyright © 2013 International Association for the Study of Lung Cancer Terms and Conditions

5 FIGURE 4 Effect of CQ on erlotinib-induced inhibition of cell-cycle progression and apoptosis in H322 and H460 cells. H322 and H460 cells were treated with 2 μM of erlotinib or 10 μM of CQ, alone or in combination for 72 hours. Cells were harvested and stained with propidium iodide for assay of cell-cycle distribution by FACS analysis. Representative DNA histograms (A) and quantitative analysis of cell-cycle distribution (B) are shown. Combination with CQ did not alter erlotinib-induced G1-phase arrest, but dramatically increased the percentage of sub-G1 apoptotic cells. CQ, chloroquine; FACS, fluorescence-activated cell sorting. Journal of Thoracic Oncology 2013 8, DOI: ( /JTO.0b013e31828c7210) Copyright © 2013 International Association for the Study of Lung Cancer Terms and Conditions

6 FIGURE 5 Effect of CQ on erlotinib-induced autophagy and apoptosis. A, Cells were treated with 2 μM of erlotinib or 10 μM of CQ alone, or the combination of both agents, or with the same volume of medium containing 0.1% DMSO as a control, for 72 hours. Immunoblot analysis of cell extracts were analyzed for LC3-I and LC3-II. The levels of LC3-II were quantified by a laser densitometer, normalized to β-actin, and the levels of LC3-II were then expressed relative to control cells. B, Cells were treated as in (A), and apoptotic cells were assessed by TUNEL reaction. Data are means ± SEM of three experiments. *Indicates significantly different from control; **indicates significantly different from control cells and erlotinib-alone treated cells. C, Effect of knockdown of Atg-5 expression on erlotinib-induced apoptosis. Cells were transfected with Atg-5 or mock-siRNA for 24 hours, and then treated with 4 μM of erlotinib. After 72 hours, the number of apoptotic cells was determined by a TUNEL assay. Data are means ± SD of three independent experiments, **p < 0.01, compared with control. CQ, chloroquine; LC3,; TUNEL, terminal deoxynucleotidyl transferase dUTP nick end labeling. Journal of Thoracic Oncology 2013 8, DOI: ( /JTO.0b013e31828c7210) Copyright © 2013 International Association for the Study of Lung Cancer Terms and Conditions

7 FIGURE 6 Effect of HCQ + erlotinib on tumor growth in vivo. Nude mice were inoculated subcutaneously with 3 to 4 × 106 H460 (A) or H358 (B) human non–small-cell lung cancer cells. Daily oral drug treatment was begun 1 week later (time 0), as follows: vehicle control (○); erlotinib (30 mg/kg/day) (▽); HCQ (162 mg/kg/day) (△); or the combination of HCQ + erlotinib (•). A total of 21 and 19 daily doses were administered to the H358- and H460-tumor bearing mice, respectively. Tumors were measured with calipers and tumor size calculated as described in Methods. Data are means ± SEM of five mice. *Indicates significantly different from vehicle control and HCQ alone; **indicates significantly different from vehicle control, HCQ alone, and erlotinib alone, p value was less than 0.05, by analysis of variance and Newman–Keul's multiple comparison test. HCQ, hydroxychloroquine; SEM, standard error of mean. Journal of Thoracic Oncology 2013 8, DOI: ( /JTO.0b013e31828c7210) Copyright © 2013 International Association for the Study of Lung Cancer Terms and Conditions

Download ppt "The Autophagy Inhibitor Chloroquine Overcomes the Innate Resistance of Wild-Type EGFR Non-Small-Cell Lung Cancer Cells to Erlotinib  Yiyu Zou, PhD, Yi-He."

Similar presentations

Supplementary Figure 1. The effect of 17-DMAG on the growth of lung cancer cells with Met amplification Tumor cells were continuously treated with increasing.

Supplementary Figure 1. The effect of 17-DMAG on the growth of lung cancer cells with Met amplification Tumor cells were continuously treated with increasing.
Inhibition of autophagy augments 5-fluorouracil chemotherapy in human colon cancer in vitro and in vivo model  Jie Li, Ni Hou, Ahmad Faried, Soichi Tsutsumi,

Inhibition of autophagy augments 5-fluorouracil chemotherapy in human colon cancer in vitro and in vivo model  Jie Li, Ni Hou, Ahmad Faried, Soichi Tsutsumi,
Nicotinamide Phosphoribosyltransferase: A Potent Therapeutic Target in Non-small Cell Lung Cancer with Epidermal Growth Factor Receptor-Gene Mutation 

Nicotinamide Phosphoribosyltransferase: A Potent Therapeutic Target in Non-small Cell Lung Cancer with Epidermal Growth Factor Receptor-Gene Mutation 
Inducible EGFR T790M-Mediated Gefitinib Resistance in Non-small Cell Lung Cancer Cells Does Not Modulate Sensitivity to PI103 Provoked Autophagy  Flavia.

Inducible EGFR T790M-Mediated Gefitinib Resistance in Non-small Cell Lung Cancer Cells Does Not Modulate Sensitivity to PI103 Provoked Autophagy  Flavia.
Enhanced Sensitivity to Sunitinib by Inhibition of Akt1 Expression in Human Castration- resistant Prostate Cancer PC3 Cells Both In Vitro and In Vivo 

Enhanced Sensitivity to Sunitinib by Inhibition of Akt1 Expression in Human Castration- resistant Prostate Cancer PC3 Cells Both In Vitro and In Vivo 
Induction of apoptosis of lung and esophageal cancer cells treated with the combination of histone deacetylase inhibitor (trichostatin A) and protein.

Induction of apoptosis of lung and esophageal cancer cells treated with the combination of histone deacetylase inhibitor (trichostatin A) and protein.
Therapy-Resistant Cancer Stem Cells Have Differing Sensitivity to Photon versus Proton Beam Radiation  Xiaochun Zhang, MD, Steven H. Lin, MD, PhD, Bingliang.

Therapy-Resistant Cancer Stem Cells Have Differing Sensitivity to Photon versus Proton Beam Radiation  Xiaochun Zhang, MD, Steven H. Lin, MD, PhD, Bingliang.
Drug concentration (μM)

Drug concentration (μM)
The Autophagy Inhibitor Chloroquine Overcomes the Innate Resistance of Wild-Type EGFR Non-Small-Cell Lung Cancer Cells to Erlotinib  Yiyu Zou, PhD, Yi-He.

The Autophagy Inhibitor Chloroquine Overcomes the Innate Resistance of Wild-Type EGFR Non-Small-Cell Lung Cancer Cells to Erlotinib  Yiyu Zou, PhD, Yi-He.
The Epidermal Growth Factor Receptor-L861Q Mutation Increases Kinase Activity without Leading to Enhanced Sensitivity Toward Epidermal Growth Factor Receptor.

The Epidermal Growth Factor Receptor-L861Q Mutation Increases Kinase Activity without Leading to Enhanced Sensitivity Toward Epidermal Growth Factor Receptor.
Antitumor Efficacy of the Anti-Interleukin-6 (IL-6) Antibody Siltuximab in Mouse Xenograft Models of Lung Cancer  Lanxi Song, MS, Matthew A. Smith, PhD,

Antitumor Efficacy of the Anti-Interleukin-6 (IL-6) Antibody Siltuximab in Mouse Xenograft Models of Lung Cancer  Lanxi Song, MS, Matthew A. Smith, PhD,
Dual Inhibition of PI3K/AKT and MEK/ERK Pathways Induces Synergistic Antitumor Effects in Diffuse Intrinsic Pontine Glioma Cells  Y. Linda Wu, Uday Bhanu.

Dual Inhibition of PI3K/AKT and MEK/ERK Pathways Induces Synergistic Antitumor Effects in Diffuse Intrinsic Pontine Glioma Cells  Y. Linda Wu, Uday Bhanu.
Shinichi Sakamoto, Steven Schwarze, Natasha Kyprianou  European Urology 

Shinichi Sakamoto, Steven Schwarze, Natasha Kyprianou  European Urology 
Volume 66, Issue 1, Pages (July 2014)

Volume 66, Issue 1, Pages (July 2014)
Yunguang Sun, PhD, Luigi Moretti, MD, Nicholas J

Yunguang Sun, PhD, Luigi Moretti, MD, Nicholas J
Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR- Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients.

Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR- Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients.
Volume 26, Issue 2, Pages (August 2014)

Volume 26, Issue 2, Pages (August 2014)
Nicotine Induces Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor by α1 Nicotinic Acetylcholine Receptor–Mediated Activation in.

Nicotine Induces Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor by α1 Nicotinic Acetylcholine Receptor–Mediated Activation in.
Induction of E-Cadherin in Lung Cancer and Interaction with Growth Suppression by Histone Deacetylase Inhibition  Masatoshi Kakihana, MD, Tatsuo Ohira,

Induction of E-Cadherin in Lung Cancer and Interaction with Growth Suppression by Histone Deacetylase Inhibition  Masatoshi Kakihana, MD, Tatsuo Ohira,
Enhancement of paclitaxel-mediated cytotoxicity in lung cancer cells by 17-allylamino geldanamycin: in vitro and in vivo analysis  Dao M Nguyen, MD, Dominique.

Enhancement of paclitaxel-mediated cytotoxicity in lung cancer cells by 17-allylamino geldanamycin: in vitro and in vivo analysis  Dao M Nguyen, MD, Dominique.

Similar presentations

Ads by Google